Eczema, atopic dermatitis, atopic eczema
HOME is a global initiative of patients, healthcare professionals, journal editors, regulatory authorities and the pharmaceutical industry.
Aim: To develop a consensus-based core outcome set (COS) for clinical trials and clinical practice. The core outcome set is the MINIMUM that should be measured in ALL clinical trials.
Foundation of HOME
Despite the high burden of atopic eczema, evidence-based clinical care and decision making is limited by the use of multiple, unvalidated outcome measures. A systematic review ( Charman et al. 2003), showed that only 27% of the 93 included trials used a published severity scale, with the remainder using modified versions of published scales or un-named scales with no data on validity or reliability. Another systematic review ( Schmitt et al. 2007) showed that most named outcome measurements for eczema have not been tested sufficiently and do not perform adequately in terms of validity, reliability or ease of use.
HOME was founded in 2008 by Professors Hywel Williams and Jochen Schmitt to bring together the eczema research community to standardise outcome measures by agreeing a core outcome set to be included in all eczema clinical trials.
Scope of the intended COS
- Study types: Clinical Trials. A core set for clinical practice and use in registries is also being developed alongside the clinical trials core outcome set
- Region: Global scope
Involvement of stakeholders
All stakeholders: healthcare professionals, people with eczema, carers of people with eczema, pharmaceutical companies, journal editors, regulatory authorities.
Core outcome domains and instruments agreed. Now focusing on implementation of the core set
Date of updates
- Eric Simpson
- Chrsitian Apflebacher
Project team members
- HOME Executive members: Eric Simpson, Christian Apfelbacher, Jochen Schmitt, Hywel Williams, Phyllis Spuls, Kim Thomas, Norito Katoh, Yael Lesham, Louise Gerbens, Laura Howells
Responsible member of Methods group (as assigned by CS-COUSIN)